Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Wally Mastroly who wrote (2282)	4/1/1999 5:49:00 PM
From: Joe	Respond to of 4140

Thread, how is the trading of options going to affect the behavior of the price of stock? Somewhere, someone indicated trading of options would reduce the short interest. Anyone have any comments on the dynamics of this move? Was yesterday's volume at the close and all those Form T's of multi-thousand share trades a result of the specialists taking a position in the stock? From the press releases, on the PCX: Sunrise Technologies International, Inc. options will trade on the February expiration cycle. It will open with strike prices of 7 1/2, 10, and 12 1/2 and will be available for the months of May, June, August, and November. Position and exercise limits have been set at 31,500 contracts. RNU options have been allocated to lead market makers Matthew Shaffer and Patrick Ward of TFM Investment Group, who assure that the disseminated market quotes are firm for 25 contracts. On the AMEX: Sunrise options will open with strike prices of 7-1/2, 10 and 12-1/2, with position limits, of 31,500 contracts. Initial expiration months will be May, June, August and November. The specialist unit will be Charlton SLK. Joe

To: Wally Mastroly who wrote (2282)	4/1/1999 7:28:00 PM
From: majormember	Read Replies (2) \| Respond to of 4140

Wally/Joe: Just spent some time going over old APCO posts when they began trading options. I couldn't find the post I was looking for, but I think the overall feeling was that options hurt the stock as people bought the option instead of the common. Wally, you were in APCO when they began option trading, do you recall the general feeling? From a personal perspective, this news will probably get me into options again. I'm sure others feel the same, so it can't be good for the stock price short term. After FDA approval, when revenue is generated and institutions buy the common, it probably won't matter much. Skane